Trident Lifeline Limited aksje

Trident Lifeline Limited, together with its subsidiaries, manufactures and markets finished doses in India, Ghana, Kenya, Peru, Cameroon, Venezuela, and internationally. The company offers various medicinal products, including pharmaceuticals, nutraceuticals, herbals, and injectables in the form of tablets, capsules, dry powders for oral suspension, oral liquids, ointments, liquid ointments, effervescent tablets, sachets, pastes, gels, solutions, suspensions, ice gels, syrups, and creams, as well as toothpaste and mouthwash. Its products target a range of therapeutic solutions, such as antibacterial, antidiarrheal, antifungal, antimalarial, antidiabetic, dental cure, proton pump inhibitor, antiprotozoal, antihistamine, antihypertensive drugs, antiparasitic, antilipidemic drugs, multivitamins, multiminerals, and non-steroidal anti-inflammatory drugs. The company is also involved in the manufacturing of formulations under proprietary brands; contract manufacturing arrangements; manufacture, trade, and distribution of skin and hair cosmetic products; and medical devices. It exports its products. The company has a strategic alliance with National Institutes of Pharmaceutical Education and Research- Ahmedabad (NIPER-A) for the technology transfer of Vorinostat, a medication for Cutaneous T-Cell Lymphoma (CTCL). Trident Lifeline Limited was incorporated in 2014 and is based in Surat, India.